Clinical Trials
35 trialsNCT05183828 2026-06-04
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
University of Washington
Phase 4 Terminated
NCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02095184 2026-04-15
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
Phase NA Terminated
NCT05454358 2025-12-15
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Fudan University
Phase 2/3 Terminated
NCT04421547 2025-03-07
MITO32
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Terminated
NCT04289805 2025-01-31
fAMHOPE
Erasme University Hospital
Phase 4 Terminated
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT03709082 2024-03-05
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
University of Kansas Medical Center
Phase 1/2 Terminated
NCT04714619 2023-12-19
CAILA
MedSIR
Phase 2 Terminated
NCT02585388 2023-09-06
CHEOPS
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT03128619 2022-09-26
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT03874325 2022-05-31
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT02907918 2021-09-29
PALTAN
Washington University School of Medicine
Phase 2 Terminated
NCT00461773 2021-03-16
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Yale University
Phase 2 Terminated
NCT02730091 2021-02-01
VICTORIANE
Centre Hospitalier Universitaire de Besancon
Phase 3 Terminated
NCT02115048 2019-12-26
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Translational Research in Oncology
Phase 2 Terminated
NCT00908531 2019-04-29
REAL
Danish Breast Cancer Cooperative Group
Phase 3 Terminated
NCT00414076 2018-11-20
Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00651976 2018-10-15
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Terminated
NCT01484041 2018-02-09
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Georgetown University
Phase 1/2 Terminated
NCT00684216 2017-09-14
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT00549822 2017-03-22
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT00573755 2016-02-05
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT01368263 2015-04-03
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00498901 2013-05-09
Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
University of Washington
Phase 2 Terminated
NCT00263198 2013-05-07
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT01205685 2012-09-11
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00499681 2012-08-10
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00611715 2012-08-09
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00516542 2012-07-24
Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00505661 2012-04-18
Letrozole in Patients With Ovarian Tumors
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00101062 2011-06-08
Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated